Misplaced Pages

Tefibazumab: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 13:22, 16 December 2011 editAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 editsm Disambig Humanize, replaced: humanized monoclonal antibodyhumanized monoclonal antibody using AWB← Previous edit Revision as of 14:24, 12 January 2012 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacol...Next edit →
Line 1: Line 1:
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 450331798 | verifiedrevid = 470478505
| image = | image =


Line 30: Line 30:


<!--Identifiers--> <!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 521079-87-8 | CAS_number = 521079-87-8
| ATC_prefix = none | ATC_prefix = none
Line 39: Line 39:
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06054 | KEGG = D06054
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = NA | ChemSpiderID = NA



Revision as of 14:24, 12 January 2012

Pharmaceutical compound
Tefibazumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetClumping factor A
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
KEGG
Chemical and physical data
FormulaC6548H10122N1730O2034S44
Molar mass147.590 kDa g·mol
  (what is this?)  (verify)

Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis and of methicillin-resistant S. aureus.

It was developed by Inhibitex.

See also

  • MSCRAMM (microbial surface components recognizing adhesive matrix molecules)

References

  1. Clinical trial number NCT00198289 at ClinicalTrials.gov
  2. PMID 18221183
  3. John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.
Monoclonal antibodies for infectious disease and toxins
Fungal
Human
Viral
Human
Chimeric
Humanized
Bacterial
Human
Mouse
Chimeric
Humanized
Toxin
Human
Chimeric
Humanized


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: